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Complete down-regulation of low-density lipoprotein receptor activity in 
human liver parenchymal cells by P-very-low-density lipoprotein 
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The effect of LDL and ,CVLDL on the expression of the LDL receptor is studied in cultured human parenchymal cells. The high affinity binding 
of [‘L’I]LDL to cultured human parenchymal cells was down regulated to 37.3 17.9% and 24.0+2.6% of the control value. after preincubation with 
LDL or /!‘-VLDL for 22 h. respectively. When LDL receptor synthesis was blocked at 12 h a residual receptor activity of 29% IS noticed. indicating 
a half-life of LDL receptors in human parenchymal cells of 12 h. It is concluded that LDL receptor expression on human liver parenchymal cells 
is subject to complete down-regulation by BVLDL, which may be held responsible for the cholesterol-rich diet induced do&n-regulation of LDL 
receptors. I” viva. 
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I. INTRODUCTION 
Under physiological conditions two-thirds of the 
plasma LDL in man is cleared via the LDL receptor- 
mediated pathway [ 11. The majority of the LDL recep- 
tor activity is localized in the liver, the only organ where 
cholesterol can be irreversibly removed from the body 
via secretion into the bile [2]. The major role of the Iiver 
in rhe removal of LDL cholesterol from the plasma was 
clearly illustrated by the finding that liver transplanta- 
tion of a normal liver into a patient with homozygote 
familial hypercholesterolemia, which lacked the LDL 
receptor, resulted in an 8107, decrease in plasma LD.4 
cholesterol levei [3]. 
Low-density lipoprotein receptors have been iden- 
tified in the livers of a variety of animals like hamsters 
[I], rabbits [4] and rats [S]. In human liver, LDL recep- 
tor activity has been demonstrated in liver membrane 
preparations [6-81 and in cultured human parenchymal 
liver cells [9-l 11. 
Since the liver is the decisive site for the regulation of 
blood cholesterol levels, we performed studies on the 
regulation of LDL receptor activity in human liver cells. 
Knowledge of the regulation of the low density lipopro- 
tein receptor activity is mainly based on studies with 
fibroblasts [2,12] or hepatoma cell lines [13,14]. In 
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human parenchymal liver ceils it was observed that 
LDL receptors can only be down-regulated partially by 
preincubation of the cells with LDL [9-11). It was 
speculated that the inability of L.DL to block receptor 
synthesis completely, would allow the liver to take up 
LDL, even at high circulating LDL levels [I 11. Spady 
and Dietschy [15] however, showed in hamsters, that a 
diet rich in cholesterol and saturated triacylglycerols 
essentially abolished the receptor-dependent clearance 
of LDL.. from the blood. Cinder those conditions a 
specific VLDL fraction called $-VLDL is the major 
cholesterol(ester) carrying particle 1161. When 
radiolabelled fl-VLDL is injected into rats the particles 
are rapidly taken up from the blood circulation by liver 
parenchymal cells [ 17,181. 
In the present study we therefore investigated the 
regulation of LDL receptor activity in primary cultured 
human liver parenchymal cells by @-VL,DL, in order to 
test to what extent P-VLDL can be responsible for the 
complete down-regulation of liver LDL receptors. 
2. MATERIALS AND METHODS 
Ectnl calf \crum. penicillin and streptomycin were from Boehrinper 
Mannheim (~lannheim. Germany). M’illiam’5 E medium and 
knnamycin were from flow laboratories (Ir\,ine. Scotland, UK). 
Human serum albumin (fraction V) has from Sigma (St. Loui\, MO, 
USA) and ‘LcI in NaOH bras from Amcrsharrr (Buckinghamshire, 
UK). 
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Hospital Dijkrigt in Rotterdam, the Netherlands. Permission was 
given by the Medical Ethical Committee to use the remaining, not 
transplanted, part of the donor liver for scientific research. Human 
parenchymal liver cells were isolated as described before [ 191. The 
parenchymal cells were cultured in 12.well plastic culture dishes 
(22.mm diameter) at 0.5 x IO6 cells/well in William,’ E medium, sup- 
plemented with 10~0 heat-inactivated fetal calf serum, 2 m%I L- 
glutamine, 20 mlJ/ml insulin, I nM dexamethasone, 100 U penicillin, 
100 p&/ml streptomycin and 50 fig/ml kanamycin at 37°C in a 
humidified 5% CO2/95% air atmosphere. The medium was renewed 
6 h after seeding and every 24 h thereafter. The viability of the cells 
directly after isolation was between 50-77%. Experiments with 
cultured parenchymal ceils were performed between the second and 
the sixth day after seeding of the cells. At this stage the viability of the 
cells was more than 95%. The hepatocytes used in this study were 
non-dividing cells able to accumulate taurocholic acid intraceilularl~ 
to the same extent as cultured rat hepatocytes [ZO]. Furthermore, the 
cells could synthesize and secrete VLDL, LDL. HDL (with VLDL as 
the major species, namely 68 i 9%); apo B, apo A-I, apo A-II, apo E, 
apo-CII [21], albumin, and plasminogen activator inhibitor I [22]. 
Also, the transport and metabolism of thyroid hormones was 
qualitatively comparable to these processes in rat hepatocytcs [23] and 
the cells do express a specific high-affinity site for HDL [24]. 
2.3. Isolation und tuba@ of sermrr iipoproreins 
&VLDL was obtained from fasted serum of male Wistar rats that 
were maintained on a cholesterol-rich diet (Hope Farms, Vcioerden, 
The Netherlands) that included 2% cholesterol, 5% olive oil and 
U.S% cholic acid 117). LDL and VLDL were obtained from fasted 
Sera from healthy volunteers. Rat $VLDL, human LDL and human 
VLDL were isolated according to RedgraLe [25] followed by a second 
identical centrifugation. Cholesterol and choiesteryl content of LDL, 
VLDL and /3-VLDL was determined en~ymaticallg, using a CHOD- 
PAP kit (Boehringer Mannheim). LDL and fl-VLDL were iodinated 
at pH 10 by the ICI method as modified by Bilheimer [26]. 
2.4. Lipoprotein binding und ussociation b-v cultured parench,vrncrl 
crlis 
Twenty-four hours before the start of the experiments, culture 
medium was removed and replaced by Williams E medium contain- 
ing 1% (w/v) human serum albumin. Preincubations for 22 h were 
performed with human LDL, human VLDL and rat &VLDL in 
culture medium with ioio human serum albumin. At the end of the 
preincubations, cells were washed twice and incubated at 37°C for 10 
min, washed again and incubated for 30 min in culture medium. This 
washing procedure was followed by incubations for either 3 h at 4°C 
or 3 h at 37°C with [‘ZLI]LDL or with [“‘l]&VLDL with or without 
300 *g/ml unlabeled lipoprotein as indicated in the figures. At the end 
of the incubation, the medium was removed and cells were washed 
five times with an ice-cold containing 0.15 M NaCl, 50 mM Tris-HCI 
and 2.5 mM CaClz (pH 7.4) and 0.2% bovine serum albumin, follow- 
ed by two wjashes with the same solution without bovine serum 
albumin. The cells were then dissolved in 0.1 N NaOH and cell- 
associated radioactivity and protein content were measured. Binding 
of [“‘I]LDL was determined as cell-associated radioactivity after 3 h 
incubation at 4°C. Association (binding and uptake) of LDL was 
determined as cell-associated radioactivity after 3 h incubation al 
37°C. Data were statistically analyzed with a two-tailed, unpaired 
Student’s t-test. 
3. RESULTS 
The binding of [12’I]LDL to human parenchymal 
liver cells in the presence or absence of 300 pg/ml 
unlabeled LDL is shown in Fig. 1. High-affinity bin- 
ding became saturated at 25 yg of LDL per ml and the 
maxima1 binding level of [‘“SI]LDL to human paren- 
chymal liver ceils was 75 ng LDL per mg cell protein. 
The maximal high-affinity binding lever of [““I]LDL 
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Fig. I The effect of the concentration of [“‘l]LDL in the absence (0) 
or presence (c) of 300 @g/ml unlabeled LDL on the extent of binding 
to cultured human li\er parenchymal cells. Cells were not prein- 
cubated (control) or preincubated for 22 h with 100 p&ml LDL or 100 
pug/ml 0.VLDL, followed by an incubation for 3 h at 4°C with the in- 
dicated amounts of [“‘I]LDL. High-affinity binding ( n ) was derived 
by subtracting non-specific binding, which was measured in the 
presence of 3OOpg/ml unlabeled LDL, from total binding. Binding of 
[““IJLDL to parenchytnal cells ii expressed ab ng LDL per mg cell 
protein. 
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competitor Cuglml) 
Fig. 2. Comparison of the abilit, of unlabeled lipoprotcinc to compete 
with the high-affinity cell binding of [“‘l]LDL to human liver paren- 
chymal cell5. Cells \cerc Incubated for 3 h at 3 ‘(‘ \\ith IO pg’ml 
[“‘IILDL and with the indicated amount\ of LDL ( A ) or $-VLDL 
( w). High-affinity hindin g is ekprcssed a$ precentage of the tradioac- 
ti\ 11~ obtained in the absence of competitor. \% hen indicated the bars 
represent z SD 
after preincubation with 100 pg/ml LDL was 31 ng 
LDL per mg cell protein, while after preincubation with 
100 pg/ml P-VLDL the maximal binding level decreased 
to 19 ng LDL/mg cell protein. Competition ex- 
periments indicate that P-VLDL does compete \cith the 
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Fig. 3. The effect of preincubation with increasing amount5 of LDI 
(*), VLDL ( A) or $-VLDL ( n ) on high-affinity a,,ociation of 
[“‘I]LDl. with human liver parcnchymal csll,. Cells were prein- 
cubated for 2? h with the indicated amounts of LDL. VLDL or @- 
VLDL followed bq an incubation for 3 h at 37°C mith IO pg:ml 
[“‘I]I.DL. High-affinity association of [“‘I]I.DL was determined b> 
subtracting nonwpecific awxiation M hich \\a\ meawrcd in the 
presence of 300 pgiml unlabeled LDL, from total association. High- 
affinity association of [“‘I]LDL is expressed a, the percentage of the 
radioactivity obtained in the absence of LDI., VLDI. or $-VI.DL in 
the preincubation. The 100% value for high-affinity aswciation with 
human liver parenchymal cells is I 15 k I I ng of LDL per mg of cell 
protein and for high-affinity degradation 34 + 4 ng per mg of cell 
protein. \Vhen indicated the bar\ Irepresent i Sk. (n = 3). 
binding of [“‘I]LDL to human parenchymal cells with 
a similar effectivity as LDL Lvhile VLDL is clearly less 
effective (Fig. 2). 
The effect of varying ;3-VLDL, VLDL and LDL con- 
centrations during the 22 h preincubation on the exprcs- 
sion of LDL. receptors is sho\\n in Fig. 3. Prcincuba- 
tions of human parench>,mal cells with relati\,ely low 
concentrations of LDL and $-VLDL resulted already in 
a marked decrease of the cell association of [“IJLDL. 
O\:er the Lvhole range of concentrations used, prein- 
cubation with /SVLDL lowered the LDL high-affinity 
association more than LDL. At concentrations higher 
than 10 pg/ml, this difference in do\vn-regulation of 
[‘“‘IILDL association \vas significant (P<O.O5). Prein- 
cubation of human parenchymal cells with increasing 
amounts of VLDL had littlc effect on the association of 
[‘251]LDL. 
Because the regulation of LDL receptor expression is 
mediated by sterol regulation of the transcription of the 
gene encoding the L.DL Ireceptor [27], we determined 
the time course showing no\\ the LDL receptor 
diminishes in activity when the synthesis is blocked bq 
cycloheximide (Fig. 4). The relationship bethkeen the 
logarithm of the high-affinity binding of [“I]LDL and 
incubation time \\as linear, indicating a half-life of the 
receptor of approx. 12 h. This indicates that \vith a 22 
h preincubation time complete blockade of LDL recep- 
tor synthesis still results in the expression of 29wo of the 
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Fig. J. rime course of the inhibition of high-affinity binding of 
[“‘IJLDL to human parenchymal cell\ b) cyclohc\imidr. Cells \+el-e 
incubated with 5 F&I cyclohe\imidc for the indicated time followed b> 
an incubation for 3 h at -l’C’ with [“‘l]LDI High-affinity binding 
wa\ determined b! ,ubtl-acting non-speclt’ic binding, \\hich war 
mca\ured it1 the presence of 300 l~g/mI unlabeled LDL, from total 
binding. BInding of [“‘I]LDL- to par-ench)mal ccll~ I\ e\pl-e\wd as ng 
LDI. per mg of cell protcw. ln\et-I: 9amc data plotted wni 
logarithmicall). Bars !reprcsenr i SD. 
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Fig. 5. P-VLDL induced regulation of [“‘I]LDL of [“‘I]@-VLDL 
high-affinity association with human liver parenchymal cells. Cells 
were preincubated for 22 h at 37°C with the indicated amount of fi- 
VLDL, followed by an incubation for 3 h at 37°C with 10 pg/ml 
[“‘IILDL ( n ) or [‘*‘I]&VLDL (7). High-affinity association of 
[“‘IILDL or [‘*“I]fl-VLDL was determined by subtracting non- 
specific association, which was measured in the presence of 300 pg/ml 
unlabeled LDL or fi-VLDL, from total association. The data are ex- 
pressed as the percentage of radioactivity of the labeled lipoproteins 
obtained in the absence of @-VLDL in the preincubation. When in- 
dicated, bars represent k SD. 
initial amount of LDL receptors. The percentage of ex- 
pression of LDL receptor at 22 h preincubation with /3- 
VLDL under the same conditions is 24.0+-2.6%, thus 
indicating that a complete inhibition of the synthesis of 
new receptors is achieved by /3-VLDL. Preincubation 
with LDL led to an inhibition of 37.3 + 2.9% of the 
control (cf. also Fig. 1). 
For reason that the effectivity of fl-VLDL to compete 
with the binding of [“‘I]LDL to the LDL receptor does 
not differ from that of LDL, we investigated whether 
an additional recognition system for /3-VLDL on 
human parenchymal cells might explain its significantly 
higher down-regulatory potency. In Fig. 5 it is shown 
that the high-affinity association of /3-VLDL to human 
parenchymal cells is only down-regulated to 68% of the 
control value while under identical conditions for LDL 
receptors this percentage is 21%. This might indicate 
that in addition to LDL receptors, an interaction of P- 
VLDL with a second recognition system for P-VLDL 
(remnant receptor or LDL receptor related protein) can 
lead to complete suppression of LDL receptors in 
human parenchymal cells. 
4. DISCUSSION 
The availability of human parenchymal cells enabled 
a study on the regulation of the human liver LDL recep- 
tor. Because most LDL receptor activity is localized in 
the liver, regulation of LDL receptor activity in human 
parenchymal liver cells is of major importance for 
cholesterol homeostasis in man. 
We demonstrate here that a 22-h preincubation of 
cultured human liver parenchymal cells with LDL and 
fl-VLDL, leads to a decrease in high-affinity binding or 
cell association of LDL. Preincubation of parenchymal 
cells with 100 pg/ml LDL led to a decrease in binding 
and association of [iz51]LDL, but this down-regulation 
of LDL receptor activity is less efficient as compared to 
down-regulation of LDL receptors found in ex- 
trahepatic cells. LDL receptor activity in fibroblasts is 
already down-regulated for 75% after preincubation 
with only 20 pg of LDL per ml [28]. Our finding, that 
down regulation of LDL receptor activity by LDL is less 
efficient in human parenchymal cells than in 
fibroblasts, is in accordance with previously reported 
results [9-l 11. Maximal down-regulation of LDL recep- 
tors by LDL was reported to be between 35-63% [9,11]. 
However, it must be taken into account that at the com- 
monly applied preincubation time (22 h) even under 
complete blockade of LDL receptors still a high-affinity 
[“‘I]LDL binding of 29% of the control values will be 
found (as deduced from the f! for LDL receptors of 12 
h in human parenchymal cells). When this finding is 
taken into account, our data still confirm that complete 
suppression of the synthesis of LDL receptors in human 
parenchymal cells cannot be achieved with LDL itself. 
This also agrees with animal studies where at 
physiological LDL concentrations, still an LDL 
receptor-mediated uptake of LDL is noticed [I]. 
However, such studies also indicated that a diet rich in 
cholesterol and saturated triacylglycerols led to a com- 
plete suppression of the LDL receptor-mediated 
clearance, at least in hamsters [ 1.51. Our present data 
with the human parenchymal liver cells indicate that 
such a complete suppression of LDL receptor synthesis 
can be achieved by fi-VLDL while normal VLDL is 
hardly effective. 
The effectivity of P-VLDL to compete with 
[12’I]LDL binding to human parenchymal cells is not 
different from that of LDL. The greater effectivity of fl- 
VLDL to suppress the synthesis of LDL receptors as 
compared to LDL is also not related to a difference in 
cholesterol content of the lipoproteins because replot- 
ting of the data from Fig. 3 (pg cholesterol instead of pg 
apolipoprotein) does not reveal a greater efficiency of 
fl-VLDL cholesterol to suppress LDL receptors. The ex- 
planation for /3-VLDL to be more effective than LDL 
may therefore be related to the presence of an addi- 
tional recognition site on human parenchymal cells for 
/3-VLDL. It appears that the high-affinity association 
of [“‘I]fl-VLDL to human parenchymal cells is only 
down-regulated to 68% of the control value by /3-VLDL 
preincubation while the [ 125 I]LDL association under the 
same conditions is diminished to 21%. If this additional 
recognition site is the remnant receptor or the LDL 
37 
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receptor-related protein [29] cannot be deduced from 
our experiments. It is, however, clear that this specific 
P-VLDL recognition site is less sensitive to down- 
regulation by P-VLDL than the LDL receptor. 
In conclusion, our data demonstrate that the LDL 
receptor synthesis in human liver parenchymal cells is 
subject to complete down-regulation by P-VLDL. The 
complete down-regulation of LDL receptors in human 
liver parenchymal cells by P-VLDL suggest that the 
observed effect of a cholesterol-rich diet on LDL recep- 
tors in vivo may be mediated by a-VLDL and that /3- 
VLDL is thus of decisive importance for regulating 
plasma LDL cholesterol levels. 
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